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Bacterial Cell-Free Probiotics 
Using Effective Substances 
Produced by Probiotic Bacteria, 
for Application in the Oral Cavity
Tomoko Ohshima, Tomomi Kawai and Nobuko Maeda
Abstract
To avoid side effects of conventional antibiotics and disinfectants used for 
prevention of oral diseases such as dental caries, periodontitis, and oral candidiasis, 
application of probiotics has attracted attention recently. However, difficulties arise 
when applying those probiotics in the oral cavity, because exogenous probiotic 
bacteria do not colonize easily in the established oral microbiota. Even, if we are 
able to overcome the restriction of colonization by probiotic bacteria in the oral cav-
ity, it comes with the risk of dental caries due to the potential acidic environment 
generated by probiotic bacteria. To solve these problems, “biogenics,” bacterial 
cell-free probiotics using only the effective substances metabolically produced by 
probiotic bacteria, is recommended for application in the oral cavity. The concept 
and frontline of biogenic research will be introduced and discussed.
Keywords: biogenics, probiotics, oral diseases, dental caries, periodontitis, 
candidiasis
1. Introduction
More than 700 bacterial species live in the oral cavity [1, 2]. These bacteria 
form their own indigenous flora in their habitats, such as teeth, gingival sulcus, 
and tongue dorsum, making the oral environment considerably complicated. Oral 
indigenous bacteria coexist with humans and are vital for preventing colonization 
by foreign pathogenic microorganisms in the oral cavity. Such oral indigenous bac-
teria proliferate with time, and together with the extracellular polymeric substance 
(EPS) that they produce, form a biofilm visible even to the naked eye known as 
dental plaque [3–5].
It has recently been clarified that the formation of biofilms is controlled by 
quorum-sensing (QS) signals in a communication system between microorgan-
isms that sense each other’s abundance [6–8]. It has further been shown that 
microorganisms constituting a biofilm activate the expression of pathogenic 
factors when QS signaling molecules, so-called “autoinducers (AI),” act as tran-
scription factors [8].
Prebiotics and Probiotics - Potential Benefits in Nutrition and Health
2
2. The potential pathogenicity of dental plaque as oral biofilm
Oral plaque contains also dental caries and periodontal disease causing organ-
isms [9–12], and when these exert their potential pathogenicity, they are considered 
to accelerate biofilm formation even more. Generally it can be said that with 
increasing thickness of the biofilm, the bacterial metabolites build up at the bottom 
of the biofilm, and the caries and periodontitis occurrence proliferate.
Caries and periodontal diseases are called the two major dental diseases, 
and both of them occur as oral infectious diseases which are caused by specific 
bacteria known as cariogenic bacteria (such as Streptococcus mutans) and peri-
odontal pathogens (such as Porphyromonas gingivalis) growing in plaque. This 
status is interpreted as dysbiosis of the oral flora. In addition, a small number of 
fungal genus Candida is also present in the indigenous oral resident microflora, 
and some factors also cause its growth in the plaque, resulting in dysbiosis, which 
causes a major oral mucosal disease, oral candidiasis. However, there is currently 
no technique to selectively eliminate only those causative microorganisms from 
the flora.
3. Oral application of probiotics and problems
The method of preventing caries and periodontal disease is basically the 
mechanical removal of the entire plaque by brushing, etc. However in the case of 
onset of the disease, antimicrobial drugs are administered for the treatment of 
the acute phase of periodontal disease, and antifungal administration is the first 
choice for treatment of oral candidiasis. However, the use of antimicrobial agents 
has shown problems regarding adverse effects such as drug-resistant bacteria and 
allergies, indicating the limitation of chemotherapy [13]. Therefore, attention 
has recently focused on probiotic bacteria such as bifidobacteria and lactobacilli 
recognizing the usefulness for improving dysbiosis [14]. Although probiotics 
were originally intended to improve dysbiosis of the intestinal flora [15], their 
usefulness is also assumed in the dental field. Attempts have been made for direct 
use in the oral cavity to prevent diseases such as caries and periodontal disease, 
and several results have been reported [16–18]. Ishikawa et al. reported that 4 
weeks of oral administration of Lactobacillus salivarius TI 2711 (LS1) significantly 
reduced the major periodontal pathogens of P. gingivalis, Prevotella intermedia, and 
Prevotella nigrescens [19].
However, in these reports, there are few basic facts on the effects of probiotics 
on the oral flora and the antibacterial substances produced by them, so progress and 
establishment of practical applications based on the underlying mechanism has not 
been accomplished. In addition, genera Lactobacillus and Bifidobacterium, which are 
representative probiotic bacteria, exist though in minority in the oral microbiota, 
but because they metabolize sugar and produce large amounts of organic acid, the 
general understanding is that they work cooperatively with cariogenic bacteria or 
induce hypersensitivity.
As another fundamental issue, previous studies have highlighted the limitation 
of colonization and fixation of nonnatural probiotic bacteria in the intestinal tract 
[20, 21]. This phenomenon of transiency, but not permanency in colonization, is 
also relevant for probiotic applications in the oral cavity [16, 22, 23]. Even if we are 
able to address the restriction of colonization of probiotic bacteria in the oral cavity, 
it comes with the risk of dental caries due to the potential acidic environment gener-
ated by probiotic bacteria.
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4. The concept of biogenics
To overcome the above problems, “biogenics” as a new idea has been introduced. 
Biogenics is a kind of functional food, using only the ingredients, which have a 
positive effect on the host with regard to immunostimulating or immunosuppress-
ing mutagenesis, tumorigenesis, peroxidation, hypercholesterolemia, or intestinal 
putrefaction [24]. Achieving a probiotic effect by the intake of nonviable probiotic 
bacteria has been proposed in previous reports. For example, the life span of mice 
increased, when they were fed with pasteurized fermented milk [25, 26]. A signifi-
cant reduction of the Ehrlich ascites tumor growth in mice was also reported [26]. 
In addition, it was shown that heat-inactivated Enterococcus faecalis [27] or L. gasseri 
[28] showed a beneficial regulatory effect in the gut. Moreover, Nakamura et al. [29] 
found an angiotensin-I-converting enzyme (ACE) inhibitor in a Japanese sterilized 
milk beverage fermented by L. helveticus and Saccharomyces cerevisiae. The active 
substance in this fermented beverage was identified as lactotripeptide metabolically 
generated in the fermentation pathway. Follow-up studies were able to determine 
the bioactive metabolites of probiotic bacteria in addition to the antimicrobial sub-
stances, such as bacteriocin [30, 31], and other beneficial active substances, such as 
conjugated linoleic acid (CLA) [30–32], proteins or peptides [33, 34], and polyphe-
nols [35, 36]. Taking all these observations into account, biogenics, which makes 
use of the bioactive metabolites as foods or medicine, was recently advocated as a 
new concept [24, 37]. The biogenic effect is independent of the colonization and 
viability of probiotic bacteria. Hence, biogenics is the direct delivery of an isolated 
and purified active ingredient of probiotics to the local environment. This strategy 
may also be useful for oral disease prevention. It may be possible to purify the effec-
tive ingredients against oral pathogenic activity of probiotic bacteria for use in the 
biogenics process. However, this idea requires further study prior to clinical use.
5. Antibacterial substances produced by lactic acid bacteria
Research of probiotics for intestinal health has revealed several antibacterial 
substances produced by lactic acid bacteria in addition to organic acids such as lactic 
and acetic acids [38]. These are (1) hydrogen peroxide [39], (2) bacteriocins [40], 
and (3) low-molecular-weight antimicrobial substances.
5.1 Hydrogen peroxide (H2O2)
Hydrogen peroxide is produced by most lactobacilli in the presence of oxygen. 
lactobacilli possess oxidases that reduce oxygen to hydrogen peroxide, oxidizing 
substrates such as pyruvate or NADH [41]. Since they do not produce catalases, 
H2O2 does not suffer auto-degradation. H2O2 has a broad-spectrum planktonic bac-
teria, but the effect decreases dramatically on biofilm. It appears that Lactobacilli 
do not produce effective concentrations of H2O2 against fungi [42], unlike other 
bacteria [39].
5.2 Bacteriocins
Lactic acid bacteria produce bacteriocins, proteinaceous antimicrobial sub-
stances with molecular weights of several thousand daltons or more. Bacteriocins 
can be divided into five classes according to their primary structure, molecu-
lar composition, and physical and functional properties [43, 44]. However, 
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bacteriocins produced by lactic acid bacteria against S. mutans and P. gingivalis are 
not yet known. Bacteriocin L23 produced by Lactobacillus fermentum L23 [44], 
plantaricin produced by L. plantarum [45], and pentocin TV35b produced by L. 
pentosus [46] appear to be effective against the yeast form of Candida. Bacteriocins 
effective for the hyphal forms of Candida have not yet been identified [47, 48].
5.3 Low-molecular-weight antimicrobial substances
Reuterin, an antibacterial substance (also known as 3-hydroxypropionaldehyde; 
molecular weight, 74 Da; composition formula, C3H6O2), is a product of glycerol 
fermentation, which has been seen in several probiotic bacteria. These probiotic 
bacteria include not only L. reuteri [49] but also L. brevis, L. buchneri [50], and L. 
collinoides [51]. Under anaerobic conditions L. coryniformis [52] also produces a 
low-molecular-weight antimicrobial substance that does not contain amino acids 
[53]. Reuterin was found to exert its antibacterial effects by causing oxidative stress 
within the bacterial cell [54]. In addition to reuterin, the low-molecular-weight 
substances of lactobacilli, reutericyclin [55] and diacetyl [56] also showed effective-
ness against the yeast forms of Candida [57].
As the smallest peptides, diketopiperazines (DKPs, cyclic dipeptides) are known 
to possess several physiological activities, including an antimicrobial effect.
diketopiperazines are a group of cyclic organic compounds where two amino 
acids are connected by a peptide bond, forming a lactam, and it is the first peptide 
whose three-dimensional structure has been completely solved by Robert Corey 
in the 1930s [58]. Corey determined the structure of the cyclic anhydride of the 
dipeptide glycylglycine. Diketopiperazines are also biosynthesized from amino 
acids in diverse organisms including mammals and are considered to be secondary 
metabolites [59]. Although some protease enzymes, such as dipeptidyl peptidase, 
produce a dipeptide by cleavage from the protein terminus, it is known that the 
Cyclic  
dipeptide
Origin Biological function References
Cyclo(Leu-Pro) Lactobacillus casei AST18 Antifungal activity [64]
Cyclo(Phe-Pro) L. plantarum MiLAB393 Antifungal activity [65]
Cyclo(Phe-4-OH-Pro)
Cyclo(Gly-Leu) L. plantarum VTT  
E-78076
Antimicrobial activity [66]
Cyclo(Phe-Pro) L. reuteri RC-14 Antimicrobial activity [67]
Cyclo(Tyr-Pro)
Cyclo(Pro-Pro) L. amylovorus DSM  
19280
Antifungal activity [68]
Cyclo(Leu-Pro)
Cyclo(Met-Pro)
Cyclo(His-Pro)
Cyclo(Leu-Leu) L. plantarum AF1 Antifungal activity [69]
Cyclo(4-OH- 
Pro-Leu)
L. fermentum ALAL020 Antimicrobial activity [70]
Table 1. 
Diketopiperazines (cyclic dipeptide) produced by probiotic bacteria.
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resulting dipeptide cyclizes spontaneously to form a diketopiperazine. In addition, 
diketopiperazines are attractive scaffolds for drug design due to their structural 
properties such as a rigid structure, optical activity, and various side-chain struc-
tures [59]. Both natural diketopiperazines and synthetic diketopiperazines have 
been reported to possess various physiological activities including antitumor activ-
ity [60], antiviral activity [61], antibacterial activity [62], and antimicrobial activ-
ity [63]. However, there are only few reports on DKP produced by probiotic bacteria 
(Table 1). In addition, the antimicrobial mechanism is also poorly understood.
6. Anti-inflammatory substances produced by lactic acid bacteria
Periodontitis and candidiasis are both inflammatory diseases; therefore, inflam-
mation symptoms are desired to be cured by biogenics, but there are few candidates 
for that.
CLA is a general term for regioisomers and structural isomers of linoleic acid 
having a conjugated diene structure.
Diene structure means there are two double bonds with a single bond in 
between. Rumenic acid, for example, is one of the 28 isomers of CLAs and exists 
in the fat and dairy products of ruminants [71]. It is a trans fat; however, CLAs can 
also appear as cis-fats. CLAs are known to reduce the production level of IgE and 
a chemical mediator leukotriene in a rat inflammatory model [72]. However, the 
opposite effect of increasing serum C-reactive protein value and reducing serum 
adiponectin level in human by CLA supplementation was observed recently [73].
7. Understanding the property of biofilm
Most bacteria and fungi have the potential to grow in a biofilm, in an environ-
ment with liquid flow and solid surfaces. Biofilm formation, which has been experi-
mentally observed in single bacteria, is now known not only to cross species but 
also to cross the kingdom of microbes. In human bodies, such situations particularly 
exist in the resident microbiota. Microorganisms including oral pathogens have the 
potential to express pathogenic properties in biofilms, contrary to the planktonic 
type. In other words, the so-called biofilm phenotypes upregulate the production 
of EPS that block the stimuli or stress from outside the biofilm, such as antibiotics 
and disinfectants. The EPS also provides sticky intercellular binding material and 
extracellular energy storage compounds [74, 75] to promote interaction among 
contacting microbial cells [76], resulting in complex and dynamic interplay.
8. Disruption of the quorum-sensing signals
Recently, a QS inhibitor (QSI) and QS signal quencher (QQ ) molecule attracted 
attention in regard to understanding biofilm infections. Biofilm formation is 
triggered and controlled by a cell-to-cell communication process in harmony 
with the bacterial population density known as quorum-sensing system, which is 
based on small molecules termed autoinducers [77]. Some reports revealed that 
bacteriocins produced by probiotic lactobacilli such as L. acidophilus, L. plantarum, 
and L. reuteri functioned as QSI or QQ molecules [78]. It may be possible to purify 
the effective ingredients of probiotic bacteria against oral pathogenic activity in 
biofilms for use in the biogenics process. Recently, some instance of QC disruption 
by cyclic dipeptides has been reported. L. reuteri, a human vaginal isolate, was 
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capable of producing the cyclic dipeptides cyclo(L-Phe-L-Pro) and cyclo(L-Tyr-L-
Pro), inhibiting the staphylococcal quorum-sensing system driven by the AI named 
agr, to suppress the expression of toxic shock syndrome toxin-1 in S. aureus [79]. 
The report is useful for a better understanding of interspecies cell-to-cell commu-
nication between Lactobacillus and Staphylococcus and provides a hint to attenuate 
virulence factor production by bacterial pathogens. However, this idea requires 
further study before clinical application.
9. Conclusion
Biogenics is based on the concept of using the active ingredients which were 
revealed by the mechanism of oral probiotics. Biogenics is expected to be a preven-
tion method for oral diseases that can be implemented without the problems associ-
ated with the use of probiotic bacteria, namely the involvement of acids harmful to 
teeth. The emergence of resistant bacteria against naturally occurring substances 
of biogenic candidates is not yet known. Furthermore, it is possible to combine 
substances which contribute to the health of the oral cavity, with those contributing 
to systemic health, such as control substances for blood sugar level, blood pressure, 
neutral fat, antioxidants, anti-stress, immune enhancement, anti-inflammation, 
antianxiety, and antidepressants. Therefore, the progress of practical application is 
expected. However, the elucidation of the mechanism of action is still in the begin-
ning, and further study is needed.
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